Saskatchewan to expand access to new ovarian cancer treatments

November 18, 2026 - 23:15
 0  0
Saskatchewan to expand access to new ovarian cancer treatments

Public funding for Elahere and Keytruda will begin December 1, offering additional treatment options for eligible patients with advanced ovarian cancer.

Saskatchewan is expanding access to ovarian cancer treatment, announcing that two newer therapies will become publicly funded for eligible patients beginning December 1, 2026.

The province confirmed November 17 that coverage will be introduced for Elahere (mirvetuximab soravtansine) and Keytruda (pembrolizumab), providing additional options for patients whose cancer has stopped responding to standard treatments.

Approximately eight to 10 patients in Saskatchewan are expected to benefit annually from access to the therapies.

Ovarian cancer is the deadliest cancer of the female reproductive system. Because symptoms can be difficult to recognize, the disease is frequently diagnosed at an advanced stage, when treatment can be more challenging

New options for difficult-to-treat cancer

Elahere is a targeted antibody-drug conjugate designed for certain patients whose tumours express folate receptor-alpha (FRα). It delivers an anticancer agent to cells expressing the target.

Keytruda is an immunotherapy that works by helping the immune system recognize and attack cancer cells. It is used in specified treatment regimens for eligible patients.

The two medications are distinct treatment options, with eligibility determined by factors including tumour characteristics and previous treatment.

Clinical studies have demonstrated improvements in outcomes for selected patients, including delayed disease progression and longer survival. However, the treatments are not appropriate for every patient, and both require specialist assessment and monitoring.

A step forward for public access

The decision follows national reviews of clinical evidence and drug pricing negotiations through the pan-Canadian Pharmaceutical Alliance.

Canada’s Drug Agency previously recommended reimbursement of Elahere for certain patients with platinum-resistant ovarian cancer, subject to specified conditions.

The Saskatchewan announcement moves beyond the national negotiation process by establishing a provincial coverage start date.

The Saskatchewan Cancer Agency says expanded access will help provide specialized, evidence-based treatment options for patients with difficult-to-treat disease.

Ovarian Cancer Canada also welcomed the decision, noting the importance of eliminating financial barriers to newer cancer therapies.

Implications for cancer care

For oncology teams, the expanded funding represents another opportunity to personalize treatment for patients whose disease progresses despite conventional chemotherapy.

Access to specialized testing, appropriate treatment selection and ongoing monitoring will remain important considerations.

The Saskatchewan Cancer Agency received $308.6 million in provincial funding for 2026–27, supporting prevention, diagnosis, treatment, research and patient services.

Patients seeking more information about eligibility for the newly funded therapies are encouraged to consult their oncology teams.

The post Saskatchewan to expand access to new ovarian cancer treatments appeared first on Hospital News.

Apa Reaksi Anda?

Suka Suka 0
Kurang Suka Kurang Suka 0
Setuju Setuju 0
Tidak Setuju Tidak Setuju 0
Bagus  Bagus 0
Berguna Berguna 0
Hebat Hebat 0
Edusehat Platform Edukasi Online Untuk Komunitas Kesehatan Agar Mendapatkan Informasi Dan Pengetahuan Terbaru Tentang Kesehatan Dari Nasional Maupun Internasional. || An online education platform for the health community to obtain the latest information and knowledge about health from both national and international sources.